Over 90% of invasive PDACs have mutations in KRAS, which has worse clinical outcomes compared with patients who have PDAC and wild-type KRAS.

• By binding adenosine receptors 2a and 2b (A2aR and A2bR) expressed on immune cells, adenosine promotes immunosuppression by inhibiting critical components of the antitumor immune response, ultimately enabling tumors to evade immune recognition. 

• Human pancreatic tumors express high levels of CD73, which are associated with immunosuppression by inhibiting critical components of the antitumor immune response, ultimately enabling tumors to evade immune recognition. 

Integrating adenosine blockade with standard-of-care chemotherapy + Zim has a manageable safety profile consistent with that expected for each agent alone.

The Adenosine Axis in Cancer

**INTRODUCTION**

**METHODS**

**RESULTS**

**CONCLUSIONS**

**ACKNOWLEDGMENTS AND DISCLOSURES**

**REFERENCES**